Telix Pharmaceuticals Limited reported a full-year unaudited Group revenue of approximately US$804 million for FY 2025, in line with upgraded guidance. Q4 2025 unaudited Group revenue was approximately US$208 million, up 46% year-over-year, driven by successful launches and strategic collaborations. Telix’s Precision Medicine business revenue saw significant growth with the U.S. launch of Gozellix.

The company’s Precision Medicine business revenue for Q4 2025 was approximately US$161 million, up 4% quarter-over-quarter. Telix achieved major milestones including treating the first international patients in the ProstACT Global Phase 3 study and first U.S. patients in the SOLACE Phase 1 study. A strategic collaboration with Varian aims to explore the combination of radiopharmaceuticals with external beam radiation therapy.

Telix is making progress in its Therapeutics business, with advancements in various therapeutic candidates such as TLX591-Tx, TLX592-Tx, TLX250-Tx, TLX252-Tx, TLX101-Tx, and TLX090-Tx. The company is actively enrolling patients in clinical trials and preparing for regulatory approvals in multiple countries. These developments showcase Telix’s commitment to addressing unmet medical needs in oncology and rare diseases.

In the Precision Medicine business, Telix’s PSMA portfolio, including Illuccix and Gozellix, has seen significant growth. The company has secured marketing authorizations in multiple markets and is actively enrolling patients in clinical studies. Telix’s PSMA-PET imaging agents are making a positive impact on patient care and management, with continued success in commercial launches and reimbursement approvals.

Telix Pharmaceuticals Limited is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. With a strong pipeline of clinical and commercial products, Telix is positioned for continued growth and success in addressing critical unmet medical needs in oncology and rare diseases. The company is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Read more at GlobeNewswire: Telix Achieves FY 2025 Guidance with US$804M (A$1.2B)